Gastroenterology Unit, AOU Maggiore della Carita', Novara, Italy.
Eur J Gastroenterol Hepatol. 2011 Nov;23(12):1178-84. doi: 10.1097/MEG.0b013e328349923c.
The aim of this study was to assess the actual effectiveness of long-term phlebotomy by comparing histological improvement (HI) in 69 Caucasian HCV-RNA-positive CHC patients undergoing phlebotomy or receiving an interferon-based therapy without virological response [nonresponders to interferon therapy(IBT-NR)].
HI was defined by at least one point reduction of the staging score or, in the case of unchanged stage, by at least two points reduction of the grading score (Knodel's Activity Index) and was retrospectively evaluated by comparing two consecutive (56 ± 28 months apart) liver biopsies from 30 phlebotomized and 39 IBT-NR patients.
HI was observed in 15 of 30 (50%) patients treated with phlebotomy and in six of 39 (15%) IBT-NR subjects (P=0.002). Furthermore, AST, ALT, and GGT serum levels were significantly reduced only in phlebotomized patients (P ≤ 0.003) at the time of the second biopsy. Univariate and multivariate analysis showed that histological grading score before therapy (P=0.001) and phlebotomy (P=0.002) were independently predictors of HI.
HI induced by long-term phlebotomy effectively exceeds that spontaneously occurring in patients IBT-NR confirming the efficacy of iron depletion in attenuating CHC progression when other therapies have failed.
本研究旨在通过比较 69 例接受放血治疗和未接受抗病毒治疗但无病毒学应答的慢性丙型肝炎病毒(HCV)阳性慢性丙型肝炎(CHC)患者的组织学改善(HI),评估长期放血治疗的实际疗效。
HI 通过至少降低分期评分 1 分或在分期不变的情况下,降低至少 2 分(Knodel 活动指数)来定义,并通过比较 30 例接受放血治疗和 39 例未接受干扰素治疗(IBT-NR)患者的连续两次(相隔 56±28 个月)肝活检来回顾性评估。
15 例(50%)接受放血治疗的患者和 6 例(15%)IBT-NR 患者出现 HI(P=0.002)。此外,仅在接受放血治疗的患者中,AST、ALT 和 GGT 血清水平在第二次肝活检时显著降低(P≤0.003)。单因素和多因素分析显示,治疗前组织学分级评分(P=0.001)和放血治疗(P=0.002)是 HI 的独立预测因素。
长期放血治疗诱导的 HI 明显优于 IBT-NR 患者自发出现的 HI,证实了当其他治疗方法失败时,铁耗竭可有效减缓 CHC 进展。